Artificial Intelligence | News | Insights | AiThority
Binance Coin

Gazelle Diagnostic Platform, Designed for Low Resource Settings, Integrates Miniaturized Technologies With AI

0 4

8-Minute, Low-Cost Diagnostic Test for Sickle Cell Disease (SCD) Among First Approved Tests

Officials from Hemex Health joined with supportive global health leaders to launch the company’s Gazelle Diagnostic platform in time for World Sickle Cell Day.  Gazelle features a SCD test that has CE Mark and regulatory approval in India and Ghana with other registrations pending.

“Gazelle is ‘the smartphone of diagnostics’ because it integrates powerful consumer electronics, digital storage and wireless communication into a portable, multi-disease platform,” said Patti White, Hemex Health’s Co-Founder and CEO. “Our mission is focused on using these powerful, affordable technologies to improve diagnostics for those living in low resource settings.”

Recommended AI News: AiThority Interview With Elie Melois, CTO And Co-Founder At LumApps

Sickle Cell Disease – An Overlooked Global Health Problem

Sickle Cell Disease presents an enormous global health challenge. More than 500 children with SCD die daily because of lack of access to early diagnosis and treatment. In Ghana, for example, fewer than 4% of babies are tested for SCD because of high cost and limited testing locations.

“With improved access to inexpensive diagnostics and cost-effective care, children with SCD could lead relatively normal lives to achieve their highest potential,” said Professor Kwaku Ohene-Frempong, President of the Sickle Cell Foundation of Ghana.

Recommended AI News: AiThority Interview With Gabe Dalporto, CEO At Udacity

User Input Drove Design of Affordable, Accurate SCD Testing Solution

Hemex worked with endemic country healthcare experts to rethink diagnostics for low resource settings.  With this input, Hemex engineered Gazelle to make a highly accurate test for SCD and other hemoglobin variants widely available for at risk populations.  Gazelle uses the company’s proprietary microchip electrophoresis technology – a miniaturized but more advanced version of the traditional electrophoresis – that identifies and quantifies hemoglobin variants.

Novartis Biome, Tata Elxsi, Bio-Rad Partner with Hemex to Bring Gazelle from Concept to Market

Recommended AI News: AiThority Interview With Terence Jackson, Chief Information Security Officer At Thycotic

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.